RoActemra regulatory update

The Scottish Medicines Consortium recommended the use of RoActemra tocilizumab from Roche to treat active systemic juvenile idiopathic arthritis (sJIA) in patients ages >=2 years who have responded inadequately to NSAIDs and systemic corticosteroids - its approved indication. The recommendation is contingent on a patient access scheme in which Roche agreed to provide the drug at an undisclosed discount. ...